title: Antidepressants and suicide attempts in children.
abstract: OBJECTIVE
  Recent data showing possible increased risk for suicidal behavior among children and adolescents treated with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) antidepressants have created significant concern among patients, families, and providers, including concerns about the risk of individual antidepressants. This study was designed to compare the risk for medically treated suicide attempts among new users of sertraline, paroxetine, citalopram, escitalopram, and venlafaxine to risk for new users of fluoxetine.
  
  
  METHODS
  A retrospective cohort study included 36,842 children aged 6 to 18 years enrolled in Tennessee Medicaid between 1995 and 2006 who were new users of 1 of the antidepressant medications of interest (defined as filling no prescriptions for antidepressants in the preceding 365 days). Medically treated suicide attempts were identified from Medicaid files and vital records and confirmed with medical record review.
  
  
  RESULTS
  Four hundred nineteen cohort members had a medically treated suicide attempt with explicit or inferred attempt to die confirmed through medical record review, including 4 who completed suicide. The rate of confirmed suicide attempts for the study drugs ranged from 24.0 per 1000 person-years to 29.1 per 1000 person-years. The adjusted rate of suicide attempts did not differ significantly among current users of SSRI and SNRI antidepressants compared with current users of fluoxetine. Users of multiple antidepressants concomitantly had increased risk for suicide attempt.
  
  
  CONCLUSIONS
  In this population-based study of children recently initiating an antidepressant, there was no evidence that risk of suicide attempts differed for commonly prescribed SSRI and SNRI antidepressants.
authors.affiliation: Departments of Pediatrics.
authors.forename: William O
authors.initials: WO
authors.lastname: Cooper
authors.forename: S Todd
authors.initials: ST
authors.lastname: Callahan
authors.forename: Ayumi
authors.initials: A
authors.lastname: Shintani
authors.forename: D Catherine
authors.initials: DC
authors.lastname: Fuchs
authors.forename: Richard C
authors.initials: RC
authors.lastname: Shelton
authors.forename: Judith A
authors.initials: JA
authors.lastname: Dudley
authors.forename: Amy J
authors.initials: AJ
authors.lastname: Graves
authors.forename: Wayne A
authors.initials: WA
authors.lastname: Ray
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects*; D000928:Antidepressive Agents / Q000009:adverse effects*; D015331:Cohort Studies; D003863:Depression / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D018570:Risk Assessment; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D013406:Suicide, Attempted / Q000706:statistics & numerical data*
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors
keywords: antidepressants; depression; suicide